Kate Goldstein

Kate is passionate about applying innovative approaches to solve the greatest challenges in life sciences. Since joining SSI in 2011, she has worked with industry leaders to address some of the highest areas of unmet need for patients, including advancing novel modalities (gene therapy, digital diagnostics) focused in rare disease.

Kate has over 13 years of experience providing strategic and operational solutions across the Medical Office, with functional experience in Medical Affairs, Clinical Development, Clinical Operations, HEOR & Real World Evidence, Safety, Quality, and Corporate Program Management. She specializes in helping business leaders define and operationalize their corporate, clinical, medical, and organizational strategies to drive value for client organizations, investors, and ultimately, for patients.

A sampling of Kate’s work includes:

• Medical Office Design & Build: working with the Executive team to scale a gene therapy company’s Medical organization to support the transition from lab to clinic
• GMA Strategy & Plan: defining a global oncology company’s Medical strategic roadmap to build the infrastructure necessary to support near-term launch activities and long-term corporate objectives
• Gene therapy CDP: establishing the Clinical Development Plan for the first curative gene therapy, setting the industry precedent for GT clinical pathways
• Digital Diagnostic Launch: defining, building, and managing the cross-functional launch infrastructure to enable commercialization of a novel digital diagnostic tool

Kate also supports various SSI corporate initiatives, including SSI’s investment fund. Prior to SSI, Kate was a member of Deloitte’s Strategy & Operations practice, where she delivered M&A/ integration, financial management, and human capital solutions. She received her B.A. from Penn State University.